Finally, the in vitro and in vivo functional assays demonstrated that cuproptosis induced by CuET agent treatment could significantly inhibit ovarian cancer cell viability, migration and invasion as well as xenografted tumor growth where the CDKN2A expression level increased. The gene discussed is CDKN2A; the disease is ovarian carcinoma.